- Home
- INCR vs MURA Comparison
INCR vs MURA Comparison
Compare INCR & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- MURA
- Stock Information
- Founded
- INCR 1994
- MURA 2013
- Country
- INCR Israel
- MURA Ireland
- Employees
- INCR N/A
- MURA N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- MURA
- Sector
- INCR Health Care
- MURA
- Exchange
- INCR Nasdaq
- MURA Nasdaq
- Market Cap
- INCR 65.3M
- MURA 57.2M
- IPO Year
- INCR N/A
- MURA N/A
- Fundamental
- Price
- INCR $1.46
- MURA $3.34
- Analyst Decision
- INCR
- MURA Strong Buy
- Analyst Count
- INCR 0
- MURA 4
- Target Price
- INCR N/A
- MURA $16.00
- AVG Volume (30 Days)
- INCR 29.6K
- MURA 262.8K
- Earning Date
- INCR 12-24-2024
- MURA 11-13-2024
- Dividend Yield
- INCR N/A
- MURA N/A
- EPS Growth
- INCR N/A
- MURA N/A
- EPS
- INCR N/A
- MURA N/A
- Revenue
- INCR $72,420,918.00
- MURA N/A
- Revenue This Year
- INCR N/A
- MURA N/A
- Revenue Next Year
- INCR $39.30
- MURA N/A
- P/E Ratio
- INCR N/A
- MURA N/A
- Revenue Growth
- INCR N/A
- MURA N/A
- 52 Week Low
- INCR $1.17
- MURA $2.88
- 52 Week High
- INCR $3.72
- MURA $6.25
- Technical
- Relative Strength Index (RSI)
- INCR 52.10
- MURA 36.64
- Support Level
- INCR $1.30
- MURA $3.32
- Resistance Level
- INCR $1.47
- MURA $4.20
- Average True Range (ATR)
- INCR 0.05
- MURA 0.23
- MACD
- INCR 0.02
- MURA -0.08
- Stochastic Oscillator
- INCR 88.83
- MURA 3.41
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.